News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Prima Biomed (PRR.AX) to Host Investor Days in Australia


1/24/2013 8:34:26 AM

SYDNEY, AUSTRALIA--(Marketwire - January 23, 2013) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) (ISIN: US74154B2034) ("Prima", "the Company") is pleased to announce upcoming investor days at several major Australian cities in February.

Prima CEO, Matthew Lehman will host the sessions, to be held in Sydney, Melbourne, Brisbane and Perth, in the week commencing 4 February 2013.

Mr. Lehman will provide an update on the Company's business and attendees will have an opportunity for Q&A.

Details of dates and venues are provided below.

Perth
Monday, 4
th February
Parmelia Hilton Hotel, 14 Mill St, Perth
10.00am - 11.30am local time

Melbourne
Tuesday, 5
th February
Westin Melbourne Hotel, 205 Collins St, Melbourne
10.30am - 12.00noon local time

Brisbane
Wednesday, 6
th February
Hilton Brisbane Hotel, 190 Elizabeth St, Brisbane
10.00am - 11.30am local time

Sydney
Thursday, 7
th February
Radisson Blu Hotel, 27 O'Connell St, Sydney
10.30am - 12.00noon local time

Shareholders and other interested parties are kindly requested to help assure appropriate accommodations by sending an RSVP by email to enquiries@primabiomed.com.au and identify the city of attendance by Friday 1st February.

About Prima BioMed
Prima BioMed is a globally active biotechnology company. As a leader in personalized bio-therapeutic products for cancer, Prima is dedicated to leveraging its current technology and expertise to develop innovative treatment options for patients and maximize value to shareholders. Prima's lead product is CVac™, an autologous dendritic cell product currently in clinical trials for ovarian cancer patients who are in remission.


For further information please contact:

USA Investor/Media:
Ms. Jessica Brown
Prima BioMed Ltd.
+1 (919) 710-9061
Email Contact

Australia Investor/Media:
Mr. James Moses
Mandate Corporate
+61 (0) 420 991 574
Email Contact

Europe Investor/Media:
Mr. Axel Muhlhaus
edicto GmbH
+49 (0) 69 905505-52
Email Contact


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES